Zhangjiang Hi-tech Park. (Credit: Pudong government)

Alzheimer's stun­ner: Chi­nese biotech wins OK for a new drug on pos­i­tive da­ta — and they have some high-pro­file sup­port­ers

Did an ob­scure Chi­nese biotech just crack the Alzheimer’s enig­ma that’s dumb­found­ed a host of ma­jor league drug de­vel­op­ers?

Chi­na’s Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion re­vealed late Fri­day that it’s grant­ed con­di­tion­al ap­proval for Shang­hai Green Val­ley Phar­ma’s oligo­man­nate cap­sules to im­prove cog­ni­tive func­tions in pa­tients with mild-to-mod­er­ate Alzheimer’s, find­ing an overnight oa­sis in a ther­a­peu­tic desert. The de­ci­sion, which fol­lowed a fast-track re­view, was based on a pur­port­ed Phase III win that the com­pa­ny has yet to dis­sect in de­tail.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.